Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depatuxizumab mafodotin in newly diagnosed EGFR-amplified glioblastoma
NCT02573324Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2015
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of depatuxizumab mafodotin in glioblastoma (GBM) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Overall Survival at 15.5 months. Started Jan 2015; status: completed.
02
Drugs
depatuxizumab mafodotin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02573324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573324.